Salt of an androgen receptor modulator
The biphthalate salts of compound I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
1 . A crystalline 2:1 compound I:biphthalate salt of N-(3H-imidazo[4,5-B]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5-alpha-androst-1-en-17-beta-carboxamide.
2 . The crystalline Form B of claim 1 .
3 . The crystalline dihydrate of the 2:1 compound I: biphthalate salt of N-(3H-imidazo[4,5-B]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5-alpha-androst-1-en-17-beta-carboxamide of claim 1 .
4 . The dihydrate crystalline Form B of the 2:1 compound I: biphthalate salt of N-(3H-imidazo[4,5-B]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5-alpha-androst-1-en-17-beta-carboxamide of claim 3 , having an X-ray powder diffraction pattern with characteristic d-spacings of 5.65±0.1, 4.62±0.1, and 4.40±0.1 angstroms.
5 . The dihydrate crystalline Form B of the 2:1 compound I: biphthalate salt of N-(3H-imidazo[4,5-B]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5-alpha-androst-1en-17-beta-carboxamide of claim 4 , which is further characterized as having X-ray powder diffraction d-spacings of 7.41±0.1, 4.10±0.1, and 3.38±0.1 angstroms.
6 . The dihydrate crystalline Form B of the 2:1 compound I: biphthalate salt of N-(3H-imidazo[4,5-B]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5-alpha-androst-1-en-17-beta-carboxamide of claim 5 , which is still further characterized as having X-ray powder diffraction d-spacings of 3.84±0.1, 3.72±0.1 and 3.24±0.1 angstroms.
7 . The dihydrate crystalline Form B of claim 6 , which is further characterized as having a melting point about 168.7±0.5° C.
8 . The dihydrate crystalline Form B of claim 7 , which is further characterized as having a solid-state Carbon-13 nuclear magnetic resonance (NMR) spectrum with signals having chemical shift values of 13.8±0.1, 44.4±0.1, and 119.4±0.1 p.p.m.
9 . The dihydrate crystalline Form B of claim 8 , which is further characterized as having signals with chemical shift values of 28.7±0.1, 56.2±0.1, and 173.3±0.1 p.p.m.
10 . The dihydrate crystalline Form B of claim 9 , which is even further characterized as having signals with chemical shift values of 38.6±0.1, 22.1±0.1, and 158.9±0.1 p.p.m
11 . A method of making a crystalline dihydrate 2:1 biphthalate salt Form B, of N-(3H-imidazo[4,5-B]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5-alpha-androst-1-en-17-beta-carboxamide comprising:
a) dissolving N-(3H-imidazo[4,5-B]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5-alpha-androst-1-en-17-beta-carboxamide in a biphthalate solution having a pH ranging from about 2 to about 9;
b) isolating the solids;
c) rinsing the solids with a solvent; and
d) drying the solids.
12 . The method according to claim 11 , wherein the biphthalate solution is selected from ammonium biphthalate and potassium biphthalate.
13 . The method according to claim 12 , wherein the biphthalate solution includes an acid selected from sulfuric acid and formic acid.
14 . The method according to claim 13 , wherein at least one said solvent is water.
15 . The method according to claim 14 , wherein isolating the solids further comprises filtering of the solids via a vacuum filter and washing the solids with at least one wash with a solvent consisting of an aqueous solution.
16 . The method according to claim 15 wherein the aqueous solution is water.
17 . A pharmaceutical composition comprising a therapeutically effective amount of at least one substantially pure crystalline form of the 2:1 compound I:biphthalate salt of N-(3H-imidazo[4,5-B]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5-alpha-androst-1-en-17-beta-carboxamide and at least one pharmaceutically acceptable carrier.
18 . The pharmaceutical composition of claim 17 , wherein said substantially pure crystalline form is selected from dihydrate Form B, anhydrous Form C, tetrahydrate Form D, and mixtures thereof.